Below are the financial statements of Dyne Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in thousands of USD | 2024 as of 2024-12-31 | 2023 as of 2023-12-31 |
|---|---|---|
| Assets | — | — |
| Current assets | — | — |
| Cash and cash equivalents | 435,449a | 121,626a |
| Marketable securities | 206,819a | 1,474a |
| Prepaid expenses and other current assets | 17,011a | 6,275a |
| Total current assets | 659,279a | 129,375a |
| Property and equipment, net | 5,398a | 4,780a |
| Right-of-use assets | 24,615a | 28,612a |
| Restricted cash | 1,942a | 2,315a |
| Total assets | 691,234a | 165,082a |
| Liabilities and stockholders’ equity | — | — |
| Current liabilities | — | — |
| Accounts payable | 6,562a | 22,936a |
| Accrued expenses and other current liabilities | 30,846a | 23,439a |
| Lease liabilities | 4,850a | 4,720a |
| Total current liabilities | 42,258a | 51,095a |
| Lease liabilities, net of current portion | 19,138a | 22,695a |
| Total liabilities | 61,396a | 73,790a |
| Stockholders’ equity | — | — |
| Preferred stock | 0a | 0a |
| Common stock | 10a | 6a |
| Additional paid-in capital | 1,579,750a | 723,796a |
| Accumulated other comprehensive loss | 6a | 0a |
| Accumulated deficit | -949,928a | -632,510a |
| Total stockholders’ equity | 629,838a | 91,292a |
| Total liabilities and stockholders’ equity | 691,234a | 165,082a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Dyne Therapeutics’s data sources below and access millions more through our Disclosure Search.